Recent studies have centered on the intersection of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|GCGR agonist therapies and DA communication. While GCGR stimulators are widely employed for managing type 2 T2DM, their unexpected consequences on reward circuits, specifically governed by dopamine networks, are attracting consid